Négociation Corvus Pharmaceuticals, Inc. - CRVS CFD

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.